Tech Times

Gene Editing at Scale: ARPA-H Awards $160M to Mass-Produce Rare Disease Cures

ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA ®) platform to develop a new class of genetic medicines for rare ...

Optimizing RNA design with AI and an Ising machine: Encoding matters

RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...

ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement

Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.

ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform

Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...
TMCnet

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™  RNA ...
Seeking Alpha

Lilly inks RNA editing deal worth up to $1.9B with Ascidian

Boston, Massachusetts-based biotech Ascidian Therapeutics on Wednesday announced a research deal and a licensing agreement worth up to $1.9B with Eli Lilly (LLY) to develop and market kidney disease ...
TMCnet

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA ...
News Medical

Study explores how reversible RNA editing could transform future cardiovascular medicine

Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular therapies. Review: RNA ...